Engineering layered double hydroxide nanoparticles toward an efficient targeted clinical delivery system. This project will develop a more effective drug delivery system using clay nanoparticles and biofriendly serum proteins. Outcomes from this project will provide a tremendous opportunity for potent therapies of cancers, vasculature and neuronal diseases, and place Australia at the forefront of nanotechnology drug delivery research.
Special Research Initiatives - Grant ID: SR1101002
Funder
Australian Research Council
Funding Amount
$21,000,000.00
Summary
Stem Cells Australia. Despite progress in stem cell research, scientists do not understand how stem cells “decide” what to become. Stem Cells Australia will draw upon strengths within Australia’s premier stem cell research universities and institutes. This collaboration between leading bioengineering, nanotechnology, stem cell and advanced molecular analysis experts, will fast-track efforts to deliver a fundamental understanding of the mechanisms of stem cell regulation and differentiation, and ....Stem Cells Australia. Despite progress in stem cell research, scientists do not understand how stem cells “decide” what to become. Stem Cells Australia will draw upon strengths within Australia’s premier stem cell research universities and institutes. This collaboration between leading bioengineering, nanotechnology, stem cell and advanced molecular analysis experts, will fast-track efforts to deliver a fundamental understanding of the mechanisms of stem cell regulation and differentiation, and the ability to control and influence this process. Stem Cells Australia will deliver new methods for stem cell propagation and manipulation, new translational technologies for therapeutic applications, and will prepare Australia’s future stem cell scientific leaders.Read moreRead less
Electrochemical biosensors for detection of cardiac disease markers in blood. Cardiovascular diseases leading to heart failure have a prevalence of over 16 per cent in Australia. The social, economic and health burden is higher than for any other disease group. Hence, it is critically important to develop fit-for-purpose sensors of known cardiac biomarkers, which alert patients and clinicians of the risk of imminent heart failure.